In the TEAL trial (NCT02073487), the combination of T-DM1, lapatinib (a TKI), and nab-paclitaxel exhibited superior efficacy compared to standard therapy in the neoadjuvant treatment of early-stage HER2-positive breast cancer, without significant differences in safety profiles (84). This evidence concerns the gene ERBB2 and breast cancer.